An Innovation Leader in Immuno-Dermatology

Mission

An R&D anchored immuno-dermatology focused company to redefine the treatment landscape, bringing transformative solutions to patients worldwide.

Learn more

Team

Our team of co-founders is comprised of experienced dermatology and scientific experts with a mission to redefine immuno-dermatology.

Learn more

Pipeline

Alys has an R&D pipeline enabled by multi-platform technologies with over a dozen active programs with potential to transform treatment landscape across dermatologic conditions.

Learn more

Latest News

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata 27 March 2025 - Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata (AA), a chronic autoimmune disease with significant unmet medical need that often leads to significant psychological distress and a reduced quality of life.

Events

There are currently no upcoming events

An Innovation Leader in Immuno-Dermatology

Mission

Team

Pipeline

Latest News

Events

© Alys Pharmaceuticals, Inc.

Address

Useful links